SCHEMBL6184004

SCHEMBL6184004

CC(=O)c1ccc2c(c1)C(C)CO2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
HTR1A P08908 1/20 0.44
HTR1D P28221 1/20 0.44
HTR2C P28335 1/20 0.44
HCRTR2 O43614 6/20 0.43
CHRNA1 P02708 1/20 0.43
CHRNG P07510 1/20 0.43
CHRNB1 P11230 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA4 P43681 1/20 0.43
CHRND Q07001 1/20 0.43
AKR1B1 P15121 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
POLB P06746 1/20 0.40
APEX1 P27695 1/20 0.40
RECQL P46063 1/20 0.40
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16742117 0.87 TDP1 (0.50) HTR1AHTR1DHTR2CHCRTR2AKR1B1
SCHEMBL16744297 0.83 NPC1 (0.44) KDM4EHTR1AHTR1DHTR2CHCRTR2
SCHEMBL27624478 0.83 ATM (0.56) KDM4EHTR1AHTR1DHTR2CHCRTR2
SCHEMBL6181167 0.81 HTR1A (0.44) KDM4EHTR1AHTR1DHTR2CHCRTR2
SCHEMBL13563052 0.75 BACE1 (0.49) HTR1AHTR1DHTR2CHCRTR2NPC1
SCHEMBL14967154 0.73 LTB4R (0.53) KDM4EHCRTR2AKR1B1NPC1RAB9A
SCHEMBL7920992 0.73 HCRTR2 (0.45) HTR1AHTR2CHCRTR2CHRNB2CHRNA4
SCHEMBL16369463 0.72 KDM4E (0.47) KDM4ECHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL24075753 0.72 HCRTR2 (0.50) HTR1AHTR2CHCRTR2
SCHEMBL22624396 0.72 MAPK9 (0.33) KDM4EHCRTR2AKR1B1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1507530-B1 DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS HOFFMANN LA ROCHE (CH) 2005-11-02 EP disclosed
EP-1507530-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2005-02-23 EP disclosed
US-6818663-B2 AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS HOFFMANN-LA ROCHES 2004-11-16 US disclosed
US-20040006058-A1 DIAMINOTHIAZOLES CHU XIN-JIE (US) 2004-01-08 US disclosed
WO-2003097048-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006058-A1 DIAMINOTHIAZOLES CDK4, CDK1, CDK2 KDM4E 377/4885HTR1A 3390/4885HTR1D 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.